SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial…

Ascendis Pharma · PRESS-RELEASE filed Apr 8, 2026 at 08:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 8, 2026 at 08:01 ET

Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial showing that the combination of TransCon CNP and TransCon hGH led to unprecedented improvements in arm span, spinal canal dimensions, and leg alignment in children with achondroplasia. These results suggest clinically meaningful benefits beyond linear growth, which could broaden the therapeutic profile and market potential of its TransCon platform.

  • TransCon CNP + TransCon hGH combination therapy showed a mean change in arm span Z-score of +1.02 (treatment-naïve) and +0.66 (pre-treated), translating to +9.4 cm and +7.9 cm gains, respectively.
  • Mean increase in interpedicular distance (IPD) was +1.7 mm (naïve) and +1.1 mm (pre-treated) with combination therapy vs. +0.6 mm with monotherapy, indicating improved spinal dimensions.
  • Tibial femoral angle (TFA) Z-score improved by -0.86 in the combination group vs. -0.47 in monotherapy, suggesting enhanced leg straightening.
  • TransCon CNP (YUVIWEL®) was FDA-approved in February 2026; TransCon hGH (SKYTROFA®) is already approved for growth hormone deficiency and is being studied in achondroplasia.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access